A Study of LY3164530 in Participants With Cancer

Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:August 2014
End Date:March 2017
Contact:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Use our guide to learn which trials are right for you!

A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients With Advanced or Metastatic Cancer

The main purpose of this study is to evaluate the safety of a study drug known as LY3164530
in participants with cancer that is advanced and/or has spread to another part(s) of the

Inclusion Criteria

- Have advanced or metastatic cancer and be an appropriate candidate for experimental

- Have adequate organ function.

- Prior Treatments:

- Systemic treatments: Must have discontinued previous systemic treatments for
cancer and recovered from the acute effects of therapy. Participants must have

- Cytotoxic therapies or targeted agents that are small molecule inhibitors
for 5 half-lives or at least 28 days.

- Mitomycin-C or nitrosourea therapy for at least 42 days and biologic agents
for at least 28 days.

- Radiation therapy and surgery must be completed 4 weeks prior to therapy, except
for limited field radiation therapy, which must be completed 2 weeks before

- If participant is of reproductive potential, must agree to use medically approved
contraceptive precautions during the study and for three months following the last
dose of study drug.

- If the participant is a female of childbearing potential, must have had a negative
serum or urine pregnancy test within 14 days of the first dose of study drug and must
not be breast feeding.

Exclusion Criteria:

- Must not have taken an unapproved drug as treatment for any indication within the
last 28 days prior to starting study treatment.

- Must not have an active symptomatic fungal, bacterial or viral infection, including
human immunodeficiency virus (HIV) or Hepatitis A, B, or C.

- Must not have a serious preexisting medical conditions or concomitant disorders.

- Must not have leukemia.

- Must not have QT interval of >470 millisecond.

- Must not have a serious cardiac condition, such as congestive heart failure, unstable
angina pectoris, or heart attack within the last 3 months.
We found this trial at
Scottsdale, Arizona 85258
Principal Investigator: Michael Gordon
Phone: 480-860-5000
Scottsdale, AZ
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Principal Investigator: David Hong
Phone: 713-563-5844
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Houston, TX
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Amita Patnaik
Phone: 210-593-5270
San Antonio, TX
Click here to add this to my saved trials